Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
作者信息
Bryant J, Clegg A, Milne R
出版信息
BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.
Abstract
摘要
相似文献
1
Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.
2
A cost-utility analysis of interferon beta for multiple sclerosis.
Health Technol Assess. 1998;2(4):iii-54.
3
Interferon beta in multiple sclerosis.
BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.
4
[Interferon-beta in multiple sclerosis--who is going to be treated?].
Tidsskr Nor Laegeforen. 1999 Sep 10;119(21):3114.
5
[A short history of beta-interferon therapy of multiple sclerosis].
Med Klin (Munich). 2001 Sep 15;96 Suppl 1:3-9.
6
Bad decision NICE.
Lancet. 2002 Feb 2;359(9304):447. doi: 10.1016/s0140-6736(02)07582-7.
7
The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Value Health. 2002 Jan-Feb;5(1):1-2. doi: 10.1046/j.1524-4733.2002.51001.x.
8
Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
Nurs Stand. 2000;14(44):20. doi: 10.7748/ns.14.44.20.s40.
9
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Clin Ther. 2012 May;34(5):1132-44. doi: 10.1016/j.clinthera.2012.03.004. Epub 2012 Apr 27.
10
Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
N Z Med J. 2006 Apr 21;119(1232):U1939.
引用本文的文献
1
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?
J Neurol Neurosurg Psychiatry. 2001 May;70(5):574-9. doi: 10.1136/jnnp.70.5.574.
2
Drug treatment of multiple sclerosis. Clinical review was unsystematic.
BMJ. 2001 Feb 3;322(7281):299.
本文引用的文献
1
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
2
3
Gains in life expectancy from medical interventions--standardizing data on outcomes.
N Engl J Med. 1998 Aug 6;339(6):380-6. doi: 10.1056/NEJM199808063390606.
4
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191.
5
A cost-utility analysis of interferon beta for multiple sclerosis.
Health Technol Assess. 1998;2(4):iii-54.
6
Sleep apnoea and the misuse of evidence-based medicine.
Lancet. 1997 Mar 15;349(9054):803-4. doi: 10.1016/S0140-6736(05)60232-2.
7
Problems of using modelling in the economic evaluation of health care.
Health Econ. 1996 Jan-Feb;5(1):1-11. doi: 10.1002/(SICI)1099-1050(199601)5:1<1::AID-HEC183>3.0.CO;2-K.
Zotero 插件